Eli Lilly Slips as Canada Approves Generic Weight-Loss Drug [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
first such approval among Group of Seven countries.The move offers a cheaper alternative in the fast-growing obesity medicine industry. Estimates show the generic, linked to rival Novo Nordisk, will be 75% to 85% cheaper than the branded version.Eli Lilly's own therapies such as Zepbound remain under patent protection, but analysts say the development reflects a broader shift toward less expensive options. That might put pressure on cost and demand over time as patients search for more economical solutions.The Indian-produced generic medicine is also approved to treat Type 2 diabetes which might increase its potential market.Investors are also trying to gauge how soon generic competition could hit the obesity medicine market, a key growth engine for Eli Lilly.
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Novo Nordisk: Pricing Pressure And Falling Margins Make This A Value Trap (Q1 Earnings Preview) [Seeking Alpha]Seeking Alpha
- Lilly rises after boosting 2026 outlook [Seeking Alpha]Seeking Alpha
- What's the Next Big Thing After GLP-1 Drugs? CRISPR Therapeutics May Have the Answer. [Yahoo! Finance]Yahoo! Finance
- Jim Cramer Believes “Novo Nordisk Is Going to Lose a Lot of Share on the Pill to Eli Lilly” [Yahoo! Finance]Yahoo! Finance
- Denecimig (Mim8) significantly reduced annualized bleeding rate in people with hemophilia A, regardless of inhibitor status, in phase 3 data published in NEJM [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 4/27/26 - Form 6-K
- 4/20/26 - Form 6-K
- 4/20/26 - Form 6-K
- NVO's page on the SEC website